Coya Therapeutics (COYA) Retained Earnings (2021 - 2026)
Coya Therapeutics (COYA) posted Retained Earnings of $118.1 million for Q1 2026, up 12.52% sequentially from $105.0 million in Q4 2025, and up 345.9% YoY from $26.5 million in Q1 2025.
Coya Therapeutics (COYA) Retained Earnings (2021 - 2026) Analysis & Trends
Coya Therapeutics has reported Retained Earnings for 6 years, with the latest figure at $118.1 million in Q1 2026.
- Quarterly Retained Earnings rose 345.9% year-over-year to $118.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.1 million (up 345.9% YoY) and the FY2025 annual result came in at $105.0 million, up 30.73% from the prior year.
- Retained Earnings improved to $118.1 million in Q1 2026 per COYA's latest filing, from $105.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at $118.1 million in Q1 2026 and troughed at -$56.3 million in Q3 2025.
- A 5-year average of $6.1 million and a median of -$22.2 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings plunged 217.73% in 2022, then jumped 410.61% in 2024.
- Over 5 years, Retained Earnings stood at -$17.9 million in 2022, then plunged by 44.7% to -$25.9 million in 2023, then surged by 410.61% to $80.3 million in 2024, then surged by 30.73% to $105.0 million in 2025, then rose by 12.52% to $118.1 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $118.1 million, $105.0 million, and -$56.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | 119.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 119.08 Mn |
| Mar 31, 2026 | 118.14 Mn |
| Dec 31, 2025 | 104.99 Mn |
| Sep 30, 2025 | -56.30 Mn |
| Jun 30, 2025 | -54.14 Mn |
| Mar 31, 2025 | -48.04 Mn |
| Dec 31, 2024 | 80.31 Mn |
| Sep 30, 2024 | -37.80 Mn |
| Jun 30, 2024 | -33.80 Mn |
| Mar 31, 2024 | 63.45 Mn |
| Dec 31, 2023 | -25.86 Mn |
| Sep 30, 2023 | 37.21 Mn |
| Jun 30, 2023 | -23.70 Mn |
| Mar 31, 2023 | -20.61 Mn |
| Dec 31, 2022 | -17.87 Mn |
| Dec 31, 2021 | -5.62 Mn |